Cover Image
市場調查報告書

全球C型肝炎病毒(HCV)抗病毒藥市場:產品、產品管道分析

A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market

出版商 Frost & Sullivan 商品編碼 306526
出版日期 內容資訊 英文 58 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球C型肝炎病毒(HCV)抗病毒藥市場:產品、產品管道分析 A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market
出版日期: 2014年06月19日 內容資訊: 英文 58 Pages
簡介

全球HCV治療藥市場現在正朝口服治療邁進(All-oral Regimens)、今後市場環境可能會有劇烈的變化。

本報告針對全球C型肝炎病毒(HCV)抗病毒藥市場分析、提供已上市/開發中產品相關產品管道資料、治療進行狀況與成果、主要市場動向、過去、未來產品上市動向、HCV疾病資料。

第1章 摘要整理

  • 市場最新動向
  • 主要分析結果
  • C型肝炎病毒(HCV)標準治療的進化
  • 矚目企業

第2章 分析方法、對像

第3章 介紹

  • C型肝炎病毒(HCV)概要
  • 世界各地慢性HCV帶源者分佈
  • HCV基因型分類分佈狀況與相關連患者數
  • HCV抗病毒藥市場構造

第4章 競爭分析

  • 競爭環境:已上市產品與開發中產品
  • 競爭環境:測試最終階段的完全口服藥(All-oral Regimens)治療數據
  • 競爭環境:口服藥上市預定表
  • 競爭環境:測試第III期主要完全口服藥
  • 競爭環境:測試最終階段產品群:企業分類、等級分類
  • 已上市產品概要:標準治療
  • 已上市產品概要:標準治療的附加治療
  • 已上市產品概要:世界各地引進狀況
  • 產品管道產品概要:測試階段完全口服藥
  • 產品管道產品概要:測試最終階段產品開發環境
  • 產品管道產品概要:測試初期階段產品開發環境

第5章 結論與建議

  • 結論與建議
  • 法律免責事項

第6章 附錄

  • 支持決策用資料庫

第7章 關於FROST & SULLIVAN

目錄
Product Code: NE16-01-00-00-00

All-oral Regimens Revolutionize the Market

This research service focuses on antiviral therapeutics for the treatment of the hepatitis C virus (HCV). A global product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HCV. Segmentation by drug class is provided, along with supporting information such as clinical trial timelines and results, key market developments, historical and projected launch timelines, and epidemiology. The information contained in this research was derived from published sources, including disease organizations; public health organizations; company publications including annual reports, SEC filings, and press releases; government public sources; and articles in scientific journals.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Key Market Developments Since Q1 2013
  • 2. Key Findings
  • 3. Evolution of Standard of Care for HCV
  • 4. Key Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

3. INTRODUCTION

Introduction

  • 1. HCV Overview
  • 2. Global Prevalence of Chronic HCV Infection by Region
  • 3. Global HCV Genotype Distribution and Relative Prevalence
  • 4. HCV Antiviral Market-Segmentation
  • 5. HCV Antiviral Market-Segmentation (continued)

4. COMPETITIVE ANALYSIS

Competitive Analysis

  • 1. Competitive Landscape-Marketed Products and Products in Development
  • 2. Competitive Landscape-All-oral Regimens Late Stage Clinical Data
  • 3. Competitive Landscape-Projected Launch Timeline for Oral Regimens
  • 4. Competitive Landscape-Major Phase 3 Trials for All-oral Regimens
  • 5. Competitive Landscape-Major Phase 3 Trials for All-oral Regimens (continued)
  • 6. Competitive Landscape-Late Stage Assets by Company and Class
  • 7. Marketed Products Synopsis-Standard of Care
  • 8. Marketed Products Synopsis-Add-on to Standard of Care
  • 9. Marketed Products Synopsis-Global Introduction by Region
  • 10. Marketed Products Synopsis-Global Introduction by Region (continued)
  • 11. Pipeline Synopsis-All-oral Regimens in Clinical Development
  • 12. Pipeline Synopsis-All-oral Regimens in Clinical Development (continued)
  • 13. Pipeline Synopsis-All-oral Regimens in Clinical Development (continued)
  • 14. Pipeline Synopsis-Late Stage Clinical Development Landscape
  • 15. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
  • 16. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
  • 17. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
  • 18. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
  • 19. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
  • 20. Pipeline Synopsis-Early Clinical Development Landscape
  • 21. Pipeline Synopsis-Early Clinical Development Landscape (continued)
  • 22. Pipeline Synopsis-Early Clinical Development Landscape (continued)

5. CONCLUSIONS AND RECOMMENDATIONS

Conclusions and Recommendations

  • 1. Conclusions and Recommendations
  • 2. Conclusions and Recommendations (continued)
  • 3. Legal Disclaimer

6. APPENDIX

Appendix

  • 1. Decision Support Database
  • 2. Decision Support Database (continued)
  • 3. Decision Support Database (continued)
  • 4. Decision Support Database (continued)

7. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top